PEP-Therapy Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 9

PEP-Therapy General Information

Description

Developer of innovative peptides designed to offer targeted therapies for severe diseases, with an initial focus on oncology. The company's peptides are active compounds that penetrate cells and block relevant intracellular protein interactions that offer intracellular delivery of targeted therapies, enabling healthcare providers to inhibit key pathological mechanisms.

Contact Information

Website
www.pep-therapy.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Primary Office
  • Pépinière Genopole Entreprises
  • 4 rue Pierre Fontaine
  • 91058 Evry Cedex
  • France
+33 01 00 00 00 00

PEP-Therapy Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PEP-Therapy Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Secondary Transaction - Private 01-Sep-2021 000.00 Completed Clinical Trials - General
7. Later Stage VC (Series A) 19-Jul-2021 00.000 000.00 Completed Clinical Trials - General
6. Grant 22-Apr-2021 00.000 00.000 Completed Clinical Trials - General
5. Later Stage VC 31-Oct-2020 00.000 00.000 00.000 Completed Pre-Clinical Trials
4. Early Stage VC 16-Nov-2017 00.00 00.000 00.000 Completed Pre-Clinical Trials
3. Early Stage VC 00000 00.000 Completed Pre-Clinical Trials
2. Grant 01-Jan-2016 $1.4M Completed Pre-Clinical Trials
1. Seed Round 27-Apr-2015 $1.4M $1.4M 00.000 Completed Pre-Clinical Trials
To view PEP-Therapy’s complete valuation and funding history, request access »

PEP-Therapy Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
P shares 0,000 00.000000 0000.00 0000.00 00 0000.00 0.000
P shares 0,000 00.000000 000.00 000.00 00 000.00 00.000
Preference 11,250 $1.176860 $125.54 $125.54 1x $125.54 14.56%
Ordinary 19,500 $1.176860 $78.46 $78.46 1x $78.46 25.25%
To view PEP-Therapy’s complete cap table history, request access »

PEP-Therapy Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of innovative peptides designed to offer targeted therapies for severe diseases, with an initial focus on onco
Drug Discovery
Evry Cedex, France
12 As of 2022
000.00
00000000000 000.00

00000

co laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in rep
0000 000000000
Somerville, MA
00 As of 0000
00000
0000 0000-00-00
00000000 00000

000000

esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat
0000 000000000
Boston, MA
000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PEP-Therapy Competitors (28)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Finch Therapeutics Formerly VC-backed Somerville, MA 00 00000 00000000 00000
000000 00000000000 Venture Capital-Backed Boston, MA 000 00000 00000000000 00000
00000000 Formerly VC-backed Malvern, PA 00 00000 0000000000.
0000000 0000000000 Venture Capital-Backed Cambridge, MA 000 00000 00000000000 00000
00000000 Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
You’re viewing 5 of 28 competitors. Get the full list »

PEP-Therapy Patents

  • 5

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

PEP-Therapy Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3559673-B1 Cell penetrating peptides with improved internalization properties Active 22-Dec-2016 000000000
US-10947276-B2 Cell penetrating peptides with improved internalization properties Active 22-Dec-2016 000000000
US-20190337985-A1 Cell penetrating peptides with improved internalization properties Active 22-Dec-2016 000000000
CA-3086387-A1 Cell penetrating peptides with improved internalization properties Pending 22-Dec-2016 0000000000
EP-3559673-A1 Cell penetrating peptides with improved internalization properties Active 22-Dec-2016 C07K14/001
To view PEP-Therapy’s complete patent history, request access »

PEP-Therapy Executive Team (5)

Name Title Board Seat Contact Info
Antoine Prestat Co-Founder, President, Chief Executive Officer & Board Member
Fariba Némati Ph.D Co-Founder and Scientific Advisor
Angelita Rebollo Ph.D Co-Founder & Scientific Advisor
Didier Decaudin Ph.D Co-Founder & Scientific Advisor
You’re viewing 4 of 5 executive team members. Get the full list »

PEP-Therapy Board Members (7)

Name Representing Role Since
Antoine Prestat PEP-Therapy Co-Founder, President, Chief Executive Officer & Board Member 000 0000
Jean-Loup Romet-Lemonne MD Self Board Member 000 0000
Jérôme Majoie Self Board Member 000 0000
Michele Marzola Ph.D Italian Angels for Growth Board Member 000 0000
Philippe Tramoy Seventure Partners Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

PEP-Therapy Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PEP-Therapy Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Anaxago Real Estate Minority 000 0000 000000 0
Doorway Capital PE/Buyout Minority 000 0000 000000 0
i&i Prague Venture Capital Minority 000 0000 000000 0
Italian Angels for Growth Angel Group Minority 000 0000 000000 0
Fonds unique interministériel Impact Investing 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial